Marianthi Georgitsi Selected Research

aryl hydrocarbon receptor-interacting protein

10/2010	Mice with inactivation of aryl hydrocarbon receptor-interacting protein (Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression.
11/2009	Aggressive pituitary adenomas occurring in young patients in a large Polynesian kindred with a germline R271W mutation in the AIP gene.
10/2008	Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas.
3/2007	Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations.
5/2006	Pituitary adenoma predisposition caused by germline mutations in the AIP gene.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marianthi Georgitsi Research Topics

Disease

6	Pituitary Neoplasms (Pituitary Adenoma) 10/2010 - 05/2006
4	Thalassemia 04/2013 - 03/2011
4	Neoplasms (Cancer) 11/2010 - 11/2009
3	Hemoglobinopathies 04/2013 - 03/2011
2	Inflammation (Inflammations) 01/2021 - 02/2018
2	Type 2 Diabetes Mellitus (MODY) 11/2020 - 01/2020
1	Prediabetic State (Prediabetes) 10/2021
1	Hypertension (High Blood Pressure) 01/2021
1	Carotid Artery Diseases 01/2021
1	Chronic Renal Insufficiency 01/2021
1	Albuminuria 01/2021
1	Diabetic Nephropathies (Diabetic Nephropathy) 11/2020
1	Diabetes Mellitus 01/2020
1	Tics (Tic) 01/2019
1	Tic Disorders (Tic Disorder) 01/2019
1	Atherosclerosis 02/2018
1	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 01/2016
1	Sickle Cell Anemia (Hemoglobin S Disease) 10/2012
1	beta-Thalassemia (Cooley's Anemia) 10/2012
1	Autoimmune Diseases (Autoimmune Disease) 01/2012
1	Myasthenia Gravis 01/2012
1	Bipolar Disorder (Manic Depressive Psychosis) 11/2011
1	Drug-Related Side Effects and Adverse Reactions 05/2011
1	Prolactinoma (Prolactinomas) 11/2010
1	Carcinogenesis 10/2010
1	Hyperparathyroidism 08/2007
1	Carcinoid Tumor (Carcinoid) 08/2007

Drug/Important Bio-Agent (IBA)

5	aryl hydrocarbon receptor-interacting proteinIBA 10/2010 - 05/2006
4	Proteins (Proteins, Gene)FDA Link 11/2020 - 08/2007
2	Hydroxyurea (Hydrea)FDA LinkGeneric 04/2013 - 10/2012
2	GlobinsIBA 01/2012 - 03/2011
2	Growth Hormone (Somatotropin)IBA 10/2010 - 05/2006
1	Glucose (Dextrose)FDA LinkGeneric 10/2021
1	Epoxide HydrolasesIBA 01/2021
1	oxidized low density lipoproteinIBA 01/2021
1	EnzymesIBA 01/2021
1	InflammasomesIBA 11/2020
1	Biological ProductsIBA 01/2020
1	Vitamin D FDA LinkGeneric 01/2020
1	AntigensIBA 01/2019
1	LipoxygenasesIBA 02/2018
1	Citalopram FDA LinkGeneric 01/2016
1	Antidepressive Agents (Antidepressants)IBA 01/2016
1	Fetal Hemoglobin (Hemoglobin F)IBA 10/2012
1	3' Untranslated Regions (3' UTR)IBA 10/2012
1	Hemoglobins (Hemoglobin)IBA 01/2012
1	AutoantibodiesIBA 01/2012
1	LithiumIBA 11/2011
1	Pharmaceutical PreparationsIBA 05/2011
1	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 11/2010
1	Insulin-Like Growth Factor I (IGF-1)IBA 11/2010
1	Aryl Hydrocarbon Receptor Nuclear TranslocatorIBA 10/2010
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 06/2010

Therapy/Procedure

2	Radiotherapy 11/2010 - 11/2009
1	Off-Label Use 01/2016